We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
76
Scholar Rock
SRRK
$6.24B
$17.3M 0.28%
2,161,203
-4,000
-0.2% -$35.1K
FATE icon
77
Fate Therapeutics
FATE
$328M
$16.9M 0.27%
4,839,779
– –
ESPR
78
DELISTED
Esperion Therapeutics
ESPR
$16.4M 0.27%
9,944,064
– –
COR icon
79
Cencora
COR
$59.3B
$16.2M 0.26%
72,053
-17,276
-19% -$4.01M
BIO icon
80
Bio-Rad Laboratories Class A
BIO
$8.11B
$15.4M 0.25%
46,151
-109,107
-70% -$34.7M
ASTH icon
81
Astrana Health
ASTH
$2.22B
$14.7M 0.24%
254,182
+3,565
+1% +$175K
CRL icon
82
Charles River Laboratories
CRL
$10.5B
$14.4M 0.23%
73,115
-159,587
-69% -$33.2M
ONC
83
BeOne Medicines Ltd
ONC
$32.5B
$13.2M 0.21%
58,729
+33,100
+129% +$5.96M
GBIO
84
DELISTED
Generation Bio
GBIO
$9.68M 0.16%
391,886
– –
PHR icon
85
Phreesia
PHR
$651M
$9.63M 0.16%
422,406
-20,935
-5% -$490K
HUM icon
86
Humana
HUM
$48B
$9.01M 0.15%
28,440
– –
TERN
87
DELISTED
Terns Pharmaceuticals
TERN
$8.69M 0.14%
+1,042,135
New +$8.57M
OMCL icon
88
Omnicell
OMCL
$2.08B
$8.62M 0.14%
197,714
-37,658
-16% -$1.42M
ABBV icon
89
AbbVie
ABBV
$450B
$8.47M 0.14%
42,886
+682
+2% +$127K
JNJ icon
90
Johnson & Johnson
JNJ
$606B
$8.3M 0.13%
51,242
+43,445
+557% +$6.92M
LEGN icon
91
Legend Biotech
LEGN
$4.44B
$8.24M 0.13%
169,134
-200,136
-54% -$10.7M
GKOS icon
92
Glaukos
GKOS
$9.12B
$8.21M 0.13%
62,983
+7,057
+13% +$878K
AMGN icon
93
Amgen
AMGN
$198B
$8.1M 0.13%
25,152
-4,376
-15% -$1.43M
CNC icon
94
Centene
CNC
$32.8B
$6.53M 0.11%
86,708
-334,750
-79% -$24.5M
TXG icon
95
10x Genomics
TXG
$5.4B
$6.36M 0.1%
281,881
-26,430
-9% -$546K
ILMN icon
96
Illumina
ILMN
$27.9B
$5.89M 0.1%
45,196
+1,600
+4% +$197K
ALT icon
97
Altimmune
ALT
$550M
$5.3M 0.09%
863,660
+263,660
+44% +$1.79M
MRK icon
98
Merck
MRK
$313B
$4.8M 0.08%
42,233
-32,476
-43% -$3.86M
WAY
99
Waystar Holding Corp
WAY
$4.22B
$4.19M 0.07%
150,202
+202
+0.1% +$4.98K
PFE icon
100
Pfizer
PFE
$142B
$4.08M 0.07%
141,075
+52,461
+59% +$1.53M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.